TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03633396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study: NCT03471351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
Study: NCT01276938

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 21 Gy radiation
Description: 21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18 Gy radiation
Description: 18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
Study: NCT04369482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Clareon
Description: Implantation of an intraocular lens Alcon Clareon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hoya Vivinex
Description: Implantation of an intraocular lens Hoya Vivinex
Study: NCT01408615

Intervention type: DRUG
Intervention: corifollitropin alfa
Description: 100 or 150 microgram single subcutaneous injection
Study: NCT03643393

Intervention type: PROCEDURE
Group type: OTHER
Intervention: perineal rectosigmoidectomy
Description: In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
Study: NCT01690052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Description: Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
Study: NCT02685319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
Study: NCT02660177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole
Description: metamizole IV administration
Study: NCT00882440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
Study: NCT01313247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1000 mg 4 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
Study: NCT00882440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
Study: NCT01048554

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide 75mg/m2 for six continuous weeks
Study: NCT00882440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 20 mg oral tablet taken once daily for 8 weeks
Study: NCT00915954

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous administration of recombinant human IGF-1
Description: Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous administration of recombinant human IGF-1
Description: Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous administration of recombinant human IGF-1
Description: Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous injection of saline followed by a series of blood draws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous injection of saline followed by a series of blood draws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
Study: NCT02474797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasonography
Description: Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7).
Study: NCT03388034

Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: A nasopharyngeal sample collected from each nostril by swabbing

Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: A nasopharyngeal sample collected from each nostril by swabbing
Study: NCT01048554

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg every 2 weeks without interruption
Study: NCT03388034

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)
Study: NCT02909530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with EZ Shot 3Plus first
Description: Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
Study: NCT03177902

Intervention type: DRUG
Intervention: Chemotherapy
Description: Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Study: NCT00387881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate / naproxen sodium
Description: sumatriptan 85mg / naproxen sodium 500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Treximet tablets
Study: NCT05621330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study: NCT02760459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Study: NCT04649541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRX-8
Description: novel semi-synthetic polymyxin B analog.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRX-8
Description: novel semi-synthetic polymyxin B analog.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRX-8
Description: novel semi-synthetic polymyxin B analog.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water
Study: NCT03156101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BinD19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
Study: NCT03429335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching session
Description: The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching session
Description: The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just TRAC It!
Description: Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyHealth Passport
Description: MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!
Study: NCT04864756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation based learning
Description: Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
Study: NCT00793988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration-assisted anaesthesia
Description: All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Switched-off vibrating device
Description: The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
Study: NCT03443141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: The applied dressing will be embebbed in Vitamin E

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard dressing
Description: The applied dressing is a normal one without adding any product to it.
Study: NCT00206635

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
Study: NCT00681044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 70-100 mg/m2/day will be administered intravenously on Days -3 and -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: infusion of previously collected stem cells on Day 0
Study: NCT00322777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirituality Teaching Program
Description: The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirituality Teaching Program
Description: The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
Study: NCT01419002

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant RTx
Description: Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery and adjuvant chemotherapy according to German S3-guidelines
Study: NCT03217747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivuxolimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivuxolimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivuxolimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivuxolimab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study: NCT03524846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 300 MG
Description: Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 600 MG
Description: Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Study: NCT04604600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amyloid PET
Description: Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
Study: NCT01176201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337 suspension
Description: 400 mg experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLV337 capsule
Description: 5 x 200 mg immediate release capsule
Study: NCT02909530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with EZ Shot 2 19G first
Description: Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
Study: NCT02879474

Intervention type: BEHAVIORAL
Intervention: Melanoma scale questionnair
Study: NCT01013454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
Study: NCT02713282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3 month formulation (PP3M)
Description: Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
Study: NCT03701529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.